Page URL:

US National Institutes of Health put $416 million into personalised medicine

12 December 2011
Appeared in BioNews 637

The National Institutes of Health (NIH) in the US has demonstrated its intent to make personalised medicine a reality by outlining plans for projects set to cost almost half a billion US dollars. In particular, the NIH hopes its four-year plan will help identify the causes of rare genetic diseases and encourage the use of genome sequencing for the diagnosis of diseases in patients.

Genome sequencing is still predominantly a research tool, used to aid the understanding of anything from evolution to the details of cellular processes, rather than a clinical one. Its applications in patient diagnosis or treatment have been limited by the cost. However the last ten years have witnessed an almost 500,000-fold drop in the cost of sequencing. This now makes sequencing a more viable option, for example, as a means of tailoring treatment plans for people diagnosed with cancer based on predictions of how they are likely to respond to different drugs.

As the major US contributor to past genome sequencing projects including the Human Genome Project, completed in 2003, the National Human Genome Research Institute (NHGRI) is set to use the $416 million cash injection to explore the medical application for genome sequencing. Discussing the NHGRI's plan Director Dr Eric Green said: 'With the investments made over the last decade, and the new ones that we are now announcing, we believe we are moving along the path towards the realisation of genomic medicine'.

Included in the plan is an allocation of almost $90 million per year for on-going NHGRI projects such as the Cancer Genome Atlas, which catalogues genomic changes in human cancers. In addition, approximately 20 percent of the total funding has been assigned to establishing two new projects: the Mendelian Genome Centres and the Clinical Sequencing Exploratory Research Project.

The aim of the Mendelian Genome Centres initiative is to identify the genetic basis for all Mendelian diseases - those that are caused by mutations in a single gene. The causes for fewer than half of the 6,000 known Mendelian diseases that affect humans have been discovered to date, and while they are not always common, director of the program Dr Lu Wang expects that the program will 'shed light on more common, complex diseases that involve similar genes, pathways and phenotypes, and contribute to the understanding of basic human genetics'.

In contrast the Clinical Sequencing Research Project is more theoretical in nature, and aims to explore the medical, ethical and social impacts of clinical genome sequencing. 'One of the things our institute can do on behalf of all of NIH is to get data on varying overarching sets of issues around applying genomics to medicine', explained Dr Green.
Funds dedicated to personalised genetics
Nature News |  6 December 2011
NHGRI broadens sequencing program focus on inherited diseases, medical applications
EurekAlert! |  6 December 2011
U.S. Genome Centers Expand to Rare Diseases, Clinical Genomics
Science Insider |  6 December 2011
US recognises clinical importance of genome sequencing
PHG Foundation |  8 December 2011
9 February 2015 - by Dr Nicola Davis 
The US President, Barack Obama, has revealed details of a multi-agency personalised medicine research plan...
21 October 2013 - by Dr Naqash Raja 
Common gene mutations link 12 cancer types such as blood, colon and kidney, research from Washington University School of Medicine, USA, has shown...
29 April 2013 - by Ruth Retassie 
The University of Glasgow will receive £20 million to develop a research centre dedicated to personalised medicine...
5 November 2012 - by Professor Donna Dickenson 
The soaring promises made by personalised medicine advocates are probably loftier than in any other medical or scientific realm today. Francis Collins, former co-director of the Human Genome Project, wrote: 'We are on the leading edge of a true revolution in medicine, one that promises to transform the traditional "one size fits all" approach into a much more powerful strategy'...
12 March 2012 - by Maren Urner 
A single tumour can have many different genetic mutations at various locations, cancer researchers have found. In a study, two thirds of the specific genetic faults identified in tumours were not repeated in the same tumour...
28 November 2011 - by Dr Rosie Morley 
An initiative has been launched to collect genetic data from NHS cancer patients in the hope of developing new, personalised treatments....
31 October 2011 - by Dr Rebecca Robey 
The NHS must take steps to prepare for a revolution in genetics-based medicine, according to a new report by the independent think tank, the Foundation for Genomics and Public Health (the PHG Foundation). The Foundation says that rapid advances in technology will soon make it possible for individuals to have their entire genome analysed affordably, and this will have a major impact on many aspects of healthcare...
1 August 2011 - by Connie St Louis 
The intersection of racial categories and emerging genetic technology is bound to be vexed given - for example - the long history of eugenics and segregation in the United States. Although the topic has received little attention among the UK general public, pharmaceutical companies on both sides of the Atlantic are investing huge amounts of research and development into individually tailored drugs - pharmacogenetics....
18 October 2010 - by MacKenna Roberts 
The UK's Nuffield Council on Bioethics has reported that direct-to-consumer personal genetic profiling services used to predict people's genetic susceptibility for common diseases, such as Parkinson's and diabetes, are often inconclusive, misleading and can potentially cause unnecessary anxiety, complacency or distress when no treatment is available...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.